Table 1.
Country | Cohort selecting criteria | BRCA1/2 prevalence |
---|---|---|
| ||
Argentina(67, 68) | Personal or FH of BC/OC | 19.04–28.3% |
BC/OC in ≤ 40 y); FH; or AJ ancestry | ||
| ||
Bahamas (20, 21) | BC | 23% |
Unaffected women with FH of BC/OC | 2.8% | |
| ||
Brazil (69–74) | BC unselected cases | 2.3% |
FH of BC/OC | 3.4% | |
BC with FH | 13% | |
HBOC criteria | 2.8–26% | |
OC unselected | 35.5% | |
| ||
Chile (75–78) | BC/OC with FH | 7.1–20.4% |
| ||
Colombia (29) (45) (30) | BC patients | 1.2 |
BC/OC families | 24.5% | |
OC patients | 15.6% | |
| ||
Costa Rica (22) | BC with FH | 4.5% |
| ||
Cuba(23) | BC patients | 2.6% |
| ||
Mexico (43, 79) (80) (81) (46) | BC/OC unselected cases | 4.3–28% |
Early BC | 6% | |
TNBC | 23% | |
| ||
Peru(44) | Unselected cohort | 5% |
| ||
Puerto Rico(24) | BC and unaffected individuals with FH | 47.8% |
| ||
Uruguay(25) | BC with FH | 17% |
Venezuela (82) | BC cases with FH, early onset or bilateral BC | 17.2% |
US Hispanics(10) | Unselected BC patients | 1.2–4.9% |
BC= breast cancer; FH= family history; HBOC= hereditary breast and ovarian cancer; OC= ovarian cancer.